Peptide TAAs were used both as a single antigen (WT-1 or MUC1 in the caseof pancreatic cancer [65, 66]) and as an antigen mixture (MAGE1, TRP-2,gp100, HER-2, IL-13Rα2 in glioblastomas [67]; gp100, tyrosinase, MAGE-A1, -A2, -A3, MART-1 in melanoma[79]; HTLV-1 Tax peptides in T-cellleukemia and lymphoma [72], and hTERT,Her2/neu, and PADRE fragments, in ovarian cancer [75]). Here, MAGEA1 is linked to ovarian carcinoma.